Comprehensive biomarker analysis from phase II study of nivolumab in patients with thymic carcinoma

In a phase II trial of nivolumab in advanced thymic carcinoma (UMIN000022007), long SD (SD for more than 24 weeks) was seen in three patients and irAE (Gr2 or higher) was seen in four patients among 15 patients. Here, we report preplanned comprehensive biomarker analyses. We obtained tumor samples f...

Descripción completa

Detalles Bibliográficos
Autores principales: Katsuya, Yuki, Kitano, Shigehisa, Yamashita, Makiko, Ouchi, Mayu, Yagishita, Shigehiro, Hamada, Akinobu, Nakamura, Hiromi, Hosoda, Fumie, Shibata, Tatsuhiro, Motoi, Noriko, Nakayama, Takayuki, Seto, Takashi, Umemura, Shigeki, Hosomi, Yukio, Satouchi, Miyako, Nishio, Makoto, Kozuki, Toshiyuki, Hida, Toyoaki, Ohe, Yuichiro, Horinouchi, Hidehito
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9869613/
https://www.ncbi.nlm.nih.gov/pubmed/36698400
http://dx.doi.org/10.3389/fonc.2022.966527

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9869613/
https://www.ncbi.nlm.nih.gov/pubmed/36698400
http://dx.doi.org/10.3389/fonc.2022.966527

Ejemplares similares